thalidomide has been researched along with Daytime Sleepiness in 10 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide has been demonstrated to possess antitumor activity in patients with advanced hepatocellular carcinoma (HCC)." | 9.16 | Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma. ( Ch'ang, HJ; Chang, JS; Chang, YH; Chen, CH; Chen, LT; Hsu, C, 2012) |
| "Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities." | 9.11 | Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. ( Brunori, M; Candela, M; Capelli, D; Catarini, M; Corvatta, L; Leoni, P; Malerba, L; Marconi, M; Mele, A; Montanari, M; Offidani, M; Olivieri, A; Rupoli, S, 2004) |
| "13 patients with treatment-resistant multiple myeloma with advanced osteolytic lesions received combined pamidronate and thalidomide therapy." | 9.10 | Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002) |
| "Thalidomide monotherapy in relapsed/refractory multiple myeloma (MM) has a response rate of 30%." | 8.84 | A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. ( Bargou, R; Cook, G; Furkert, K; Glasmacher, A; Hahn-Ast, C; Hoffmann, F; Naumann, R; von Lilienfeld-Toal, M, 2008) |
| "Neutropenia was a dose limiting factor with half of the cases (7/14) presenting with severe neutropenia (grade 3-4), but a response was observed in all of them on administration of G-CSF." | 6.71 | [Single-agent thalidomide for advanced and refractory multiple myeloma]. ( Fujimura, K; Imagawa, J; Katayama, Y; Kimura, A; Noda, M; Okikawa, Y; Okita, H; Sakai, A; Takimoto, Y, 2003) |
| "Thalidomide has been demonstrated to possess antitumor activity in patients with advanced hepatocellular carcinoma (HCC)." | 5.16 | Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma. ( Ch'ang, HJ; Chang, JS; Chang, YH; Chen, CH; Chen, LT; Hsu, C, 2012) |
| "Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities." | 5.11 | Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. ( Brunori, M; Candela, M; Capelli, D; Catarini, M; Corvatta, L; Leoni, P; Malerba, L; Marconi, M; Mele, A; Montanari, M; Offidani, M; Olivieri, A; Rupoli, S, 2004) |
| "13 patients with treatment-resistant multiple myeloma with advanced osteolytic lesions received combined pamidronate and thalidomide therapy." | 5.10 | Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002) |
| "The introduction of novel antimyeloma therapies, including thalidomide, lenalidomide and bortezomib, has expanded treatment options for patients with multiple myeloma." | 4.86 | Management of treatment-related adverse events in patients with multiple myeloma. ( Mateos, MV, 2010) |
| "Thalidomide monotherapy in relapsed/refractory multiple myeloma (MM) has a response rate of 30%." | 4.84 | A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. ( Bargou, R; Cook, G; Furkert, K; Glasmacher, A; Hahn-Ast, C; Hoffmann, F; Naumann, R; von Lilienfeld-Toal, M, 2008) |
| "Disease progression was observed in 14 (45%) patients." | 2.73 | Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma. ( Amato, RJ; Malya, R; Rawat, A, 2008) |
| " The pharmacokinetic analysis were performed on 16 patients." | 2.72 | Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. ( Allegrini, G; Amatori, F; Bocci, G; Cerri, E; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Marcucci, L; Masi, G, 2006) |
| "Neutropenia was a dose limiting factor with half of the cases (7/14) presenting with severe neutropenia (grade 3-4), but a response was observed in all of them on administration of G-CSF." | 2.71 | [Single-agent thalidomide for advanced and refractory multiple myeloma]. ( Fujimura, K; Imagawa, J; Katayama, Y; Kimura, A; Noda, M; Okikawa, Y; Okita, H; Sakai, A; Takimoto, Y, 2003) |
| " The dose-response relationship, if any, of thalidomide for renal cell carcinoma is unclear." | 2.70 | A phase II study of thalidomide in advanced metastatic renal cell carcinoma. ( Damico, LA; Elias, L; Meng, G; Minor, DR; Monroe, D; Suryadevara, U, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (80.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amato, RJ | 1 |
| Malya, R | 1 |
| Rawat, A | 1 |
| von Lilienfeld-Toal, M | 1 |
| Hahn-Ast, C | 1 |
| Furkert, K | 1 |
| Hoffmann, F | 1 |
| Naumann, R | 1 |
| Bargou, R | 1 |
| Cook, G | 1 |
| Glasmacher, A | 1 |
| Mateos, MV | 1 |
| Ch'ang, HJ | 1 |
| Hsu, C | 1 |
| Chen, CH | 1 |
| Chang, YH | 1 |
| Chang, JS | 1 |
| Chen, LT | 1 |
| Minor, DR | 1 |
| Monroe, D | 1 |
| Damico, LA | 1 |
| Meng, G | 1 |
| Suryadevara, U | 1 |
| Elias, L | 1 |
| Okikawa, Y | 1 |
| Takimoto, Y | 1 |
| Noda, M | 1 |
| Imagawa, J | 1 |
| Katayama, Y | 1 |
| Sakai, A | 1 |
| Okita, H | 1 |
| Fujimura, K | 1 |
| Kimura, A | 1 |
| Offidani, M | 1 |
| Corvatta, L | 1 |
| Marconi, M | 1 |
| Malerba, L | 1 |
| Mele, A | 1 |
| Olivieri, A | 1 |
| Brunori, M | 1 |
| Catarini, M | 1 |
| Candela, M | 1 |
| Capelli, D | 1 |
| Montanari, M | 1 |
| Rupoli, S | 1 |
| Leoni, P | 1 |
| Allegrini, G | 1 |
| Di Paolo, A | 1 |
| Cerri, E | 1 |
| Cupini, S | 1 |
| Amatori, F | 1 |
| Masi, G | 1 |
| Danesi, R | 1 |
| Marcucci, L | 1 |
| Bocci, G | 1 |
| Del Tacca, M | 1 |
| Falcone, A | 1 |
| Ciepłuch, H | 1 |
| Baran, W | 1 |
| Hellmann, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Clinical and Mechanistic Study of Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma[NCT00155272] | Phase 1/Phase 2 | 19 participants | Interventional | 2005-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for thalidomide and Daytime Sleepiness
| Article | Year |
|---|---|
A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Constipation; De | 2008 |
Management of treatment-related adverse events in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disorders of Excessive Somnolence; Gastrointestina | 2010 |
7 trials available for thalidomide and Daytime Sleepiness
| Article | Year |
|---|---|
Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Constipation; Di | 2008 |
Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Chemokine | 2012 |
A phase II study of thalidomide in advanced metastatic renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Constipation; Disorders of Excessive Somnolence; Endothelial Gro | 2002 |
[Single-agent thalidomide for advanced and refractory multiple myeloma].
Topics: Aged; Aged, 80 and over; Constipation; Disease Progression; Disorders of Excessive Somnolence; Femal | 2003 |
Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.
Topics: Aged; Aged, 80 and over; Constipation; Disorders of Excessive Somnolence; Dose-Response Relationship | 2004 |
Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2006 |
Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2002 |
1 other study available for thalidomide and Daytime Sleepiness
| Article | Year |
|---|---|
[Potential side effects of thalidomide].
Topics: Constipation; Disorders of Excessive Somnolence; Drug Eruptions; Humans; Immunosuppressive Agents; L | 2006 |